Harrow, Inc. · NASDAQ:HROW
Harrow — Jefferies Global Healthcare Conference 2026
22 slides from Harrow's conference presentation, Nov 16, 2026
Slide 1: Investor Presentation, Jefferies Global Healthcare Conference London
Investor Presentation Jefferies Global Healthcare Conference London | November 2026
Slide 2: Safe Harbor
Jefferies Global Healthcare Conference | London | November 2026 Safe Harbor 2 This presentation contains “forward-looking statements” as defined in the U.S. Private Securities Litigation Reform Act of 1995. You are cautioned not to rely on these forward-looking statements. These statements are based
Slide 3: Harrow at a Glance: We Are Ophthalmic Pharma
Jefferies Global Healthcare Conference | London | November 2026 H A R R O W A T A G L A N C E Harrow. We Are Ophthalmic Pharma. 3 Founded to deliver safe, effective, accessible, and affordable eye medications. The Broadest U.S. Portfolio In Eye Care More prescription eye products than anyone else in
Slide 4: Financial Snapshot and 2026 Outlook
Jefferies Global Healthcare Conference | London | November 2026 F I N A N C I A L S Financial Snapshot and 2026 Outlook Five years of growth. A record third quarter. 4 $72.5M $88.6M $130.2M $199.6M $272.3M $357.5M 2021 2022 2023 2024 2025 2026 Guidance Annual Revenue ($M) 2026 Is The Guidance Midpoi
Slide 5: Three Drivers of Value: Driver One, Growth
Jefferies Global Healthcare Conference | London | November 2026 T H R E E D R I V E R S O F V A L U E Driver One: Growth 5 1 Growth Three brands. All early in their run. VEVYE | IHEEZO | TRIESENCE 2 Operating Leverage The platform is built. Revenue now grows faster than cost. Four Sales Teams | One
Slide 6: Three Brands Drive the Growth
Jefferies Global Healthcare Conference | London | November 2026 D R I V E R O N E : G R O W T H Three Brands Drive The Growth Q3 2026 vs. Q3 2025 6 D R Y E Y E D I S E A S E $39.7M 75% G R O W T H Revenue vs. last year Total prescriptions up 83% O C UL A R A N E S TH E S I A $25.3M 15% G R O W T H R
Slide 7: VEVYE: A Big Market, Barely Treated
Jefferies Global Healthcare Conference | London | November 2026 D R I V E R O N E : G R O W T H | V E V Y E VEVYE: A Big Market, Barely Treated 93% of diagnosed U.S. dry eye patients are not on a prescription. 7 38M+ Americans with dry eye symptoms 16.4M Diagnosed U.S. adults 9.0M Moderate-to-severe
Slide 8: VEVYE: Record Quarter, Revenue Up 75% vs. Q3 2025
Jefferies Global Healthcare Conference | London | November 2026 D R I V E R O N E : G R O W T H | V E V Y E VEVYE: Record Quarter, Revenue Up 75% vs. Q3 2025 Total prescriptions, net price, and insurance coverage are all rising. 8 $16.0M $21.5M $18.6M $22.6M $25.9M $20.9M $29.4M $39.7M Q4 '24 Q1 '25
Slide 9: IHEEZO: Under 2% of a 14M-Procedure Market
Jefferies Global Healthcare Conference | London | November 2026 D R I V E R O N E : G R O W T H | I H E E Z O IHEEZO: Under 2% of a 14M-Procedure Market A patented gel ocular anesthetic for in-office eye procedures. Paid under its own product-specific permanent J-code. 9 38,931 48,755 51,545 62,814
Slide 10: TRIESENCE: Unit Demand Up 110% vs. Q3 2025
Jefferies Global Healthcare Conference | London | November 2026 D R I V E R O N E : G R O W T H | T R I E S E N C E TRIESENCE: Unit Demand Up 110% vs. Q3 2025 FDA-approved preservative-free injectable steroid for the eye 10 4,367 5,547 9,551 10,2659,934 14,603 20,022 Q1 Q2 Q3 Q4 TRIESENCE Customer U
Slide 11: Three Drivers of Value: Driver Two, Operating Leverage
Jefferies Global Healthcare Conference | London | November 2026 T H R E E D R I V E R S O F V A L U E Driver Two: Operating Leverage 11 1 Growth Three brands. All early in their run. VEVYE | IHEEZO | TRIESENCE 2 Operating Leverage The platform is built. Revenue now grows faster than cost. Four Sales
Slide 12: The Commercial Platform Is Built and Paid For
Jefferies Global Healthcare Conference | London | November 2026 D R I V E R T W O : O P E R A T I N G L E V E R A G E 2026: The Commercial Platform Is Built and Paid For Same cost base from Q2 to Q3 drove 41% more revenue … our hiring is paying off. 12 SG&A as a Share Of Revenue 84% First Half 2026
Slide 13: Flat SG&A; 78% Incremental Adjusted EBITDA Conversion
Jefferies Global Healthcare Conference | London | November 2026 D R I V E R T W O : O P E R A T I N G L E V E R A G E Flat SG&A; 78% Incremental Adjusted EBITDA Conversion Q3 revenue up $28.6M vs. Q2 on flat SG&A ($53.3M in Q2, $53.1M in Q3). 2026 by quarter, Q1 to Q3 actuals. 13 $44.2M $70.7M $99.3
Slide 14: Three Drivers of Value: Driver Three, Growth Acceleration
Jefferies Global Healthcare Conference | London | November 2026 T H R E E D R I V E R S O F V A L U E Driver Three: Growth Acceleration 14 1 Growth Three brands. All early in their run. VEVYE | IHEEZO | TRIESENCE 2 Operating Leverage The platform is built. Revenue now grows faster than cost. Four Sa
Slide 15: A New Product Every Year Into 2030
Jefferies Global Healthcare Conference | London | November 2026 D R I V E R T H R E E : G R O W T H A C C E L E R A T I O N A New Product Every Year Into 2030 Each team grows its lead brand today, and adds new product launches in growing categories sold to the same customers. 15 1 2 3 2026 LAUNCHED
Slide 16: New Revenue Is Already Arriving
Jefferies Global Healthcare Conference | London | November 2026 D R I V E R T H R E E : G R O W T H A C C E L E R A T I O N New Revenue Is Already Arriving Two products already selling in 2026. A bigger one comes in 2027. 16 D R Y E Y E N A S A L S P RA Y >$30M Expected 2027 revenue • The only nasal
Slide 17: G-MELT: Sedation Without The IV
Jefferies Global Healthcare Conference | London | November 2026 D R I V E R T H R E E : G R O W T H A C C E L E R A T I O N | G - M E L T G-MELT: Sedation Without The IV A tablet under the tongue. No needle. No opioid. 17 • 3 mg midazolam plus 50 mg ketamine in one tablet. • Dissolves in ~3 seconds
Slide 18: Catalysts Through 2027
Jefferies Global Healthcare Conference | London | November 2026 D R I V E R T H R E E : G R O W T H A C C E L E R A T I O N Catalysts Through 2027 What to watch between now and the end of next year. 18 Q4 2026 G-MELT NDA Submission Ahead of the first-half 2027 plan By year-end 2026 TYRVAYA First Rev
Slide 19: Investment Summary: Why Harrow
Jefferies Global Healthcare Conference | London | November 2026 S U M M A R Y Investment Summary: Why Harrow Three drivers of value, each already showing up in the numbers. 19 1 Growth Three core brands (VEVYE, IHEEZO and TRIESENCE), all early in their growth. $99.3M Record Q3 2026 revenue, up 39%;
Slide 20: Thank You
Thank You Growth. Operating leverage. Growth acceleration. Jefferies Global Healthcare Conference London | November 2026 Mike Biega VP, Investor Relations & Communications mbiega@harrowinc.com
Slide 21: The Full Portfolio
Jefferies Global Healthcare Conference | London | November 2026 A P P E N D I X | E X H I B I T The Full Portfolio 21 Commercial Products Product Use Sales Team VEVYE Dry eye disease Ocular Surface TYRVAYA Dry eye disease (nasal spray) Ocular Surface FRESHKOTE PF Lubricant eye drops (OTC) Ocular Sur
Slide 22: Sources
Jefferies Global Healthcare Conference | London | November 2026 A P P E N D I X | S O U R C E S Sources 22 Slide 4. Q3 2026 press release, including the condensed balance sheet. Annual revenue: Harrow Corporate Presentation, November 2026, slide 7. Implied Q4 Adjusted EBITDA of more than $33M: 29th